Journal Guide

Advances in Therapy is an international peer-reviewed journal dedicated to the rapid publication of studies in clinical medicine, including research on existing drugs and drugs in development across a range of therapeutic areas.The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research papers, drug reviews, and other contributions to drug therapy, diagnosis, instrumentation, and related fields.Please note: Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited.  The author assigns the exclusive right to any commercial use of the article to Springer.  For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/2.5

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents.The journal includes current opinion on contentious issues and emerging areas, and definitive reviews on a broad range of topics relating to the optimum management of cardiovascular disorders.

An invaluable journal specifically designed as a forum for discussing, evaluating and disseminating the latest information about dermatological disorders.The American Journal of Clinical Dermatology provides healthcare practitioners with objective, peer-reviewed information covering all aspects of the management of dermatological conditions, particularly the place in therapy of newer and established agents and procedures.

Applied Health Economics and Health Policy is an international peer-reviewed journal designed to communicate the latest applied information in health economics and health policy.
Areas of interest include:  
• Economic analysis of all aspects of healthcare interventions.
• Economic analysis of health policy initiatives.
• Cost of illness studies.
• Evaluation of methodologies.
• Analysis of pricing and reimbursement systems.  

An essential resource for R&D professionals and clinicians with an interest in biologic therapies.BioDrugs covers the development and use of biotechnology-based pharmaceuticals and innovative technologies for the treatment of human disease.

Cardiology and Therapy is a fully open access, internationally peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3-4 weeks from acceptance). Emphasis is placed on the publication of high-quality practical and clinical research around new and existing therapies in all areas of cardiology, including interventional cardiology. Studies relating to diagnosis, health economics, outcomes research, patient care, management, and education are also encouraged. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, drug reviews, case reports, and short communications. Moving forward from traditional publishing, Cardiology and Therapy offers a range of additional features designed to increase visibility and readership. As such, each paper is accompanied by a bulleted slide summary giving a time-efficient overview of the content to a wider readership. All submissions have the option to include slide sets, video components, animations, and/or interactive case studies.Cardiology and Therapy publishes supplements and special issues (in English or a local language). Material appropriate for supplements/special issues include: sponsored meeting proceedings, roundtable discussions, workshop reports, case series, and collections of articles on the same topic. All articles are subject to peer review, and must adhere to the IJCME and GPP policies on acknowledgments/disclosures. Proposals for supplements are welcomed, and should be addressed to nicola.cartridge@springer.comFor authors: Upon acceptance of your article for publication, you will be required to pay the article open access fee of £175/€200/$260 per printed page. This will enable you to keep the copyright: you are simply assigning the exclusive right to any commercial use of the article to Springer. Your article will be immediately and permanently available with open, access.

Clinical Drug Investigation covers:Clinical trialsOutcomes researchPharmacoeconomics studiesPharmacoepidemiology studiesPharmacodynamic and pharmacokinetic studiesApplication of drug-delivery technology in healthcare

Clinical Pharmacokinetics is the major review journal in the area of clinical pharmacokinetics, the study of drug disposition in the human body, which is an integral part of drug development and rational use.

Dermatology and Therapy is an open access, international, peer-reviewed, rapid-publication journal dedicated to the publication of cutting-edge research, treatment, and aesthetic interventions in dermatology.Emphasis is placed on articles that investigate the clinical aspects of dermatology, such as skin pharmacology:  skin development and aging, prevention, diagnosis, and management of skin disorders: and research into dermal structures and pathology. The journal also provides insights into all aspects relating to aesthetic dermatology, such as skin maintenance: photodamage and photoprotection: rejuvenation: restoration: and dermatological surgery and lasers. Pharmacoeconomic, epidemiological outcomes, and quality of life studies are also be encouraged, along with research relating to patient management.The journal is of interest to a broad audience of pharmaceutical and eye care professionals and publishes original research papers, drug reviews, case reports, and short communications.Moving forward from traditional publishing, Dermatology and Therapy offers a range of additional features designed to increase visibility and readership. Each paper is accompanied by a bulleted slide summary, giving a time-efficient overview of the content to a wider readership. Articles also have the option to include slide sets, videos, animations, and/or interactive case studies. The QR code on the front page of each article links readers back to the journal website to view these extra features.Dermatology and Therapy publishes supplements and special issues (in English or a local language). Material appropriate for supplements/special issues include: sponsored meeting proceedings, roundtable discussions, workshop reports, case series, and collections of articles on the same topic. All articles are subject to peer review, and must adhere to the IJCME and GPP policies on acknowledgments/disclosures. Proposals for supplements are, welcomed, and should be addressed to clare.shepherd@springer.comFor authors: Upon acceptance of your article for publication, you will be required to pay the article open access fee of £175/€200/$260 per printed page. This will enable you to keep the copyright: you are simply assigning the exclusive right to any commercial use of the article to Springer. Your article will be immediately and permanently available with open access.

 

Diabetes Therapy is an international, open access, peer-reviewed journal focused on cutting-edge research in the prevention, treatment, management, and education of diabetes and related disorders including obesity and metabolic syndromes. Emphasis is placed on the publication of high-quality articles covering preclinical, clinical (phase 1-4), and postmarketing studies on new and existing therapies and devices. Pharmacoeconomic, epidemiological, outcomes, and quality of life studies are also encouraged, along with research relating to patient management and education. The journal aims to promote better management and care of patients with diabetes and provides expert opinion on current advances in the field.Diabetes Therapy publishes original research, reviews, case reports, and short communications.Diabetes Therapy publishes supplements and special issues (in English or a local language). Material appropriate for supplements/special issues include: sponsored meeting proceedings, roundtable discussions, workshop reports, case series, and collections of articles on the same topic. All articles are subject to peer review, and must adhere to the IJCME and GPP policies on acknowledgments/disclosures. Proposals for supplements are welcomed, and should be addressed to nicola.cartridge@springer.comFor authors: Upon acceptance of your article for publication, you will be required to pay the article open access fee of £175/€200/$260 per printed page. This will enable you to keep the copyright: you are simply assigning the exclusive right to any commercial use of the article to Springer. Your article will be immediately and permanently available with open access.

Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:   

• Overviews of contentious or emerging issues. 
• Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. 
• In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. 
• Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
• Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
• Editorials and commentaries on topical issues.

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original clinical research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

For 30 years Drugs & Aging has been delivering essential information on the most important aspects of drug therapy to researchers and healthcare professionals involved in the care of older patients.

Through a program of reviews and original research articles, the journal addresses major issues relating to drug therapy in older adults, including the management of specific diseases or disorders, particularly those associated with aging, age-related physiological changes impacting drug therapy, and issues related to drug utilization and prescribing.

As a hybrid journal, Drugs & Aging does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs & Aging offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

Drugs & Therapy Perspectives provides concise, authoritative review articles to aid drug formulary and prescribing decisions. It is a digest of the latest drug knowledge covering the most important aspects of clinical therapeutics, including:Questions and answers on the clinical use of drugs.Comparisons of the features of various drugs, using differential feature tables.Current thinking on disease management.Step-by-step clinical decision-making, illustrated with patient care algorithms.First reports of serious adverse drug reactions.Clinically useful pharmacodynamics and pharmacokinetics.Developments in pharmacoeconomics and other research that have a bearing on clinical practice.All material is prepared by Adis editors and medical writers, unless otherwise noted. The preparation of material is not supported by any external funding. All review articles are subject to peer review by members of the journal's international editorial board and/or other experts.

Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs - Real World Outcomes has a broad scope, encompassing studies investigating drug utilisation, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.

Drugs in R&D is an international, peer reviewed, open access, online only journal, which provides timely information on emerging drug classes and new treatments for specific disorders in an ‘open access’ format for all to review. Original research and reviews from all phases of clinical development are included, with a strong link to clinical practice. Healthcare decision makers are thus provided with clinically applicable knowledge about the likely place in therapy of a drug.Journal issues comprise:·        Original research on new drugs, including clinical trials:·        New research on established drugs.·        R&D Insight reports:Short communications and letters to the editor are welcomed and will be considered for publication. Reviews may also be considered. All manuscripts are subject to peer review by international experts.

The European Journal of Drug Metabolism and Pharmacokinetics addresses all aspects of pre-clinical and clinical pharmacokinetics, including drug disposition, drug metabolism, drug transport, drug interactions, bioavailability and biopharmacy. The journal welcomes publications in the field of pharmacokinetic modeling. Analytical methods validation and bioequivalence studies will not be considered for publication. The journal publishes original articles, short preliminary communications, review articles on special topics, and conference proceedings.The European Journal of Drug Metabolism and Pharmacokinetics publishes four issues a year.

Infectious Diseases and Therapy is an open access, internationally peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3-4 weeks from acceptance). Emphasis is placed on high quality pre-clinical, clinical (phases 1-4), and real world research around the discovery,  development, and use of infectious disease therapies. The journal also encourages diagnostic,  pharmacoeconomic, public health, educational, and quality of life studies as well as research around the prevention and management of infectious disease. Areas of focus include, but are not limited to, chronic infections, vaccines, drug-resistant pathogens, microbiology, epidemiology, and tropical, emergent, and sexually-transmitted diseases.The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research papers, drug reviews, case reports, and short communications. Each paper is accompanied by a bulleted slide summary to give a time-efficient overview of the content. All submissions have the option to include slide sets, video components, animations, and/or interactive case studies.Infectious Diseases and Therapy publishes supplements and special issues (in English or a local language). Material appropriate for supplements/special issues include: sponsored meeting proceedings, roundtable discussions, workshop reports, case series, and collections of articles on the same topic. All articles are subject to peer review, and must adhere to the IJCME and GPP policies on acknowledgments/disclosures. Proposals for supplements are welcomed, and should be addressed to clare.shepherd@springer.comFor authors: Upon acceptance of your article for publication, you will be required to pay the article open access fee of £175/€200/$260 per printed page. This will enable you to keep the copyright: you are simply assigning the exclusive right to any commercial use of the article to Springer., Your article will be immediately and permanently available with open access.

Insights into the latest molecular diagnostic and pharmacogenomic techniques and their use in personalized medicine.